Hussein Tawbi, MD, PhD, highlights the importance of BRAF mutations and LDH levels in diagnosing patients with metastatic melanoma and guiding treatment.
Dosing and Regimen Changes Promote Tolerability in Advanced Melanoma
March 14th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.
Read More